FDA Approves Myqorzo for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

dailywire.com - 08/Jan 12:29

On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for...

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

dailywire.com - 08/Jan 12:29

On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for...

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

drugs.com - 12/Jan 22:01

January 12, 2026 -- The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes...

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

drugs.com - 12/Jan 22:01

January 12, 2026 -- The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes...

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

drugs.com - 09/Jan 20:01

LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted...

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

drugs.com - 09/Jan 20:01

LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted...

FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes

drugs.com - 11:01

TUESDAY, Jan. 20, 2026 — A U.S. Food and Drug Administration (FDA)-approved device for treating ADHD in kids simply doesn’t work, a new...

FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes

drugs.com - 11:01

TUESDAY, Jan. 20, 2026 — A U.S. Food and Drug Administration (FDA)-approved device for treating ADHD in kids simply doesn’t work, a new...

FDA Approves First Oral Drug for Thalassemia Anemia

medindia.net - 12/Jan 14:57

FDA approves Mitapivat, the first oral treatment for thalassemia anemia, helping reduce transfusion needs and raise hemoglobin levels in adults.

FDA Misses Deadline to Ban Formaldehyde in Hair Straighteners

drugs.com - 08/Jan 15:01

THURSDAY, Jan. 8, 2026 — The U.S. Food and Drug Administration (FDA) has again missed a deadline to propose a ban on chemicals in...

Rubriques :

FDA Approves Myqorzo for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Articles similaires

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes

FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes

FDA Approves First Oral Drug for Thalassemia Anemia

FDA Misses Deadline to Ban Formaldehyde in Hair Straighteners

Les derniers communiqués